NASDAQ · Biotechnology

NeuBase Therapeutics, Inc. (NBSE) Stock

$0.38 -1.56% NASDAQ: NBSE Healthcare

Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes.

Valuation

MetricValue
Price$0.38
Market Cap$1.42M
P/E Ratio-0.02
P/B Ratio0.03
P/S Ratio0.00
EPS (TTM)$-21.08
52-Week High$4.44
52-Week Low$0.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-88.62%
ROA-104.71%
ROCE-116.80%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.26
Current Ratio5.92

Annual Financials (USD)

Metric20182019202020212022
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-26.0M$-17.0M$-27.0M$-33.0M
Net Profit$-13.0M$-27.0M$-17.0M$-26.0M$-34.0M
EPS$-93.57$-65.49$-17.60$-18.80$-21.08
Op Margin—————

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$12.0M$13.0M$34.0M$64.0M$33.0M
Total Liabilities$1.0M$3.0M$3.0M$10.0M$10.0M
Cash$4.0M$10.0M$32.0M$53.0M$23.0M
Borrowings$0$0$0$7.0M$6.0M

Latest News

Vallourec to supply pipes for Atapu 2 offshore project in Brazil Offshore Technology · Jul 23, 2026 Micron and Sandisk Are Surging: Can the Rally Last Through 2027? Motley Fool · Jul 23, 2026 1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds StockStory · Jul 23, 2026 Solowin Expands FinTech Network, Enters Latin American Market MT Newswires · Jul 23, 2026 CRIF India Launches Chennai Chapter of 'Credit Goes to HER' to Strengthen Women's Leadership in the Credit Ecosystem PR Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-9.0M$-3.0M$-11.0M$-19.0M$-29.0M
Investing Cash Flow$1.0M$-1.0M$-2.0M$-4.0M$-1.0M
Financing Cash Flow$0$14.0M$33.0M$42.0M$0
Net Cash Flow$-9.0M$10.0M$22.0M$21.0M$-30.0M
Free Cash Flow$-9.0M$-3.0M$-11.0M$-20.0M$-29.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.48
FCF Yield-2079.10%
Quick Ratio5.95
Interest Coverage-1385.55
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASLNASLAN Pharmaceuticals Limited $0.60 -14.27% -0.06 $777.12M 0.00%
CWBRCohBar, Inc. $0.41 +0.00% -0.10 $1.19M 0.00%
CYTOAltamira Therapeutics Ltd. $0.30 +100.00% -0.02 $1.13M 0.00%
IMPLImpel Pharmaceuticals Inc. $0.04 -27.27% -0.01 $956000 0.00%
NMTRQ9 Meters Biopharma, Inc. $0.00 — — $1446 0.00%

About NeuBase Therapeutics, Inc.

Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.

NeuBase Therapeutics, Inc. is headquartered in US.

NeuBase Therapeutics, Inc. (NBSE) stock trades at $0.38 with a market capitalization of $1.42M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.03, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.36 and $4.44, and currently trades 91.4% below its 52-week high.

On profitability, NeuBase Therapeutics, Inc. generates a return on equity (ROE) of -88.62%, return on capital employed of -116.80%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.neubasetherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides